Recent secondary market transactions have driven Neuralink’s implied valuation sharply higher to the $42–58.8 billion range as of early October 2026, up more than 400 percent from the roughly $9.7 billion post-money Series E in June 2025. Strong private-equity demand, fueled by clinical trial progress with over 20 human implants and FDA breakthrough designation for the Blindsight vision-restoration device, underpins trader sentiment. Limited primary funding data and ongoing preclinical work, including recent canine implants, sustain optimism despite the company’s early-stage status and modest participant numbers. Key near-term catalysts include additional trial readouts, potential regulatory milestones, and any new capital raises before year-end that could reset or confirm secondary pricing levels.